Givastomig
Givastomig (ABL111, TJ033721) is a bispecific antibody (BsAb) inhibitor. Givastomig can specifically binds to Claudin18.2 (CLDN 18.2) on the surface of cancer cells and 4-1BB (CD137, TNFRSF9) on the surface of activated T cells and natural killer (NK) cells. Givastomig is engineered to contain a single Fc-domain mutation (asparagine to alanine) to eliminate Fc-effector function. Givastomig-bound cell lines expressing a range of CLDN18.2 levels with high affinity and induced 4-1BB activation only in the context of CLDN18.2 binding. Givastomig can be used for the study of colon carcinoma[1].
Product Specifications
CAS Number
2762499-30-7
Product Name Alternative
TJ-CD4B; ABL111; TJ033721
UNSPSC
12352203
Hazard Statement
H302, H315, H319, H335
Target
Claudin; TNF Receptor
Type
Inhibitory Antibodies
Related Pathways
Apoptosis; Cytoskeleton
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/givastomig.html
Purity
98.556
Molecular Weight
(201.929 kDa)
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Dry Ice
Storage Conditions
-80°C
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
